Notice2024-21742
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 24, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 185 (Tuesday, September 24, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 185 (Tuesday, September 24, 2024)]
[Notices]
[Pages 77875-77876]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-21742]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Haiqing Li at 240-627-3708, or
<a href="/cdn-cgi/l/email-protection#2f4346474e466f424e46430141464701484059"><span class="__cf_email__" data-cfemail="ea8683828b83aa878b8386c4848382c48d859c">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Monoclonal Antibodies That Bind to the Underside of Influenza Viral
Neuraminidase
Description of Technology
Current influenza vaccines mainly induce antibodies against the
surface glycoprotein hemagglutinin (HA) that block viral attachment to
its host receptors and viral membrane fusion to the host cell. The
immunodominant head region of HA undergoes antigenic drift and
antibodies directed to the head confer little cross-protections between
strains or subtypes.
Researchers at the Vaccine Research Center of the National
Institute of Allergy and Infectious Diseases have identified human
monoclonal antibodies that each bind distinct epitopes on the less
abundant yet critical viral surface glycoprotein neuraminidase (NA).
These antibodies, isolated from convalescent individuals with confirmed
influenza A H3N2 infection, inhibit viral propagation of a wide range
of human H3N2, swine-origin variant H3N2, and H2N2 viruses and confer
pre-exposure and post-exposure protection from lethal H3N2 infection in
mice. Cryo-electron microscopy revealed that two of these antibodies
bind non-overlapping epitopes covering the underside of the NA head,
thus defining a potential vaccine target.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications
<bullet> Prevention or treatment of influenza infection
<bullet> Testing influenza antigens
Competitive Advantages
<bullet> Improved breadth of protection relative to influenza HA-
targeting antibodies
Development Stage: Preclinical.
Inventors: Masaru Kanekiyo (NIAID), Sarah Andrews (NIAID), Julia
Lederhofer (NIAID), Yaroslav Tsybovsky (Leidos Biomedical Research).
[[Page 77876]]
Publications: Protective human monoclonal antibodies target
conserved sites of vulnerability on the underside of influenza virus
neuraminidase. Lederhofer, Julia et al. Immunity, Volume 57, Issue 3,
574-586.e7.
Intellectual Property: PCT/US2023/071194 filed 28 July 2023 (NIH
Ref. No. E-177-2022).
Licensing Contact: To license this technology, please contact
Haiqing Li at 240-627-3708, or <a href="/cdn-cgi/l/email-protection#81ede8e9e0e8c1ece0e8edafefe8e9afe6eef7"><span class="__cf_email__" data-cfemail="a3cfcacbc2cae3cec2cacf8dcdcacb8dc4ccd5">[email protected]</span></a>, and reference E-177-
2022.
Dated: September 18, 2024.
Christopher M. Kornak,
Acting Deputy Director, Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-21742 Filed 9-23-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 24, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.